An Israeli-American pharmaceutical company is preparing to launch a first phase of clinical trials for what could become the first oral coronavirus vaccine.
According to the Israeli newspaper “Jerusalem Post”, the Israeli company, Auramid, for the pharmaceutical industry, announced, over the weekend, a joint venture with the American company “Primas Biotech” to develop a new oral vaccine.
The newspaper pointed out that the Israeli company relies on technology developed by the Hadassah University Medical Center.
She explained that the two companies have jointly formed the “ORAFEX Medical” company, where the prospective vaccine will depend on the expertise of “Auramid” related to oral drugs, and the expertise of Primas in the field of vaccine.
And contact took place between the two companies early this year, according to Nadav Kidron, CEO of “Auramid”, who explained that the administrations of the two companies realized that they could revolutionize the market.
Kidron said: “The oral vaccine against Corona will remove many obstacles that prevent the rapid and widespread distribution of the vaccine, which may enable people to take the vaccine by themselves at home.”